CAS NO: | 1000578-26-6 |
包装 | 价格(元) |
10mg | 电议 |
50mg | 电议 |
Cas No. | 1000578-26-6 |
化学名 | (2S)-N,N-dimethyl-8-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydronaphthalen-2-amine |
Canonical SMILES | CC1=NN(C(C)=C1C2=CC=CC3=C2C[C@](N(C)C)([H])CC3)C |
分子式 | C18H25N3 |
分子量 | 283.41 |
溶解度 | <28.34mg/ml in ethanol;<28.34mg/ml in DMSO |
储存条件 | Desiccate at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
半岛bd体育手机客户端 描述 | AS 19 is a potential 5-HT7 receptor agonist with an IC50 value of 0.83 nM [1]. 5-HT7 receptor plays a role in the control of both sleep and circadian rhythms. This receptor may also play a role in other CNS disorders including cognitive disturbances, anxiety and migraine probably via both central and peripheral mechanisms [2]. By signaling through the 5-HT7 receptor, serotonin provides an accessory signal to enhance the activation of the T-cell. Compared with saline-treated controls, the proliferation of T-cell from PCPA-treated mice was significantly reduced. The PCPA inhibition efficacy ranged from approximately 18% to 49%. Addition of exogenous 5-HT at 1 μM completely restored the proliferation of the T-cell. Similar to exogenous 5-HT, addition of AS19 at 1 μM also completely restored T-cell proliferation after 48 hours [4]. SB-258719 is a selective 5-HT7 receptor antagonist. When AS-19 at a dose of 10 mg/kg was co-administered with SB-258719 at the same dose, which produced no effect on its own, the anti-hyperalgesic effect of AS-19 was reversed in both hotplate and tail-flick tests. That meant AS-19 exerts anti-hyperalgesic effect via 5-HT7 receptors [3]. SB269970 is also a selective 5-HT7 receptor antagonist. Some rats were prepared with a second intrathecal catheter and were pretreated with 7μl SB269970 at a concentration of 5mM. At all time points, AS-19-induced PMF was abolished by SB269970 pretreatment. This meant AS-19 elicited PMF via the activation of 5-HT7 receptor [5]. References: |